Ilana Fogelman
Fondateur chez LifeTech Research, Inc.
Profil
Ilana Fogelman is the founder of C2N Diagnostics LLC, founded in 2007, and LifeTech Research, Inc., founded in 2003.
At LifeTech Research, Inc., she holds the title of Chief Operating Officer starting in 2003.
Currently, Ms. Fogelman is the Chief Executive Officer at miCure Therapeutics Ltd since 2022 and also serves as a Director at Rare-X.
In the past, she worked as an Analyst at Merrill Lynch, Pierce, Fenner & Smith, Inc. in 2002.
From 2008 to 2015, she was the Managing Partner at LifeTech Development Partners LP.
Ms. Fogelman also held a position as a Principal at Salomon Smith Barney.
She completed her graduate degree at Harvard University in 1993 and earned a doctorate degree from the University of Sao Paulo.
Postes actifs de Ilana Fogelman
| Sociétés | Poste | Début |
|---|---|---|
LifeTech Research, Inc.
 LifeTech Research, Inc. Investment Banks/BrokersFinance Founded in 2003, LifeTech Research, Inc. is an investment research, technology development and due diligence firm located in Edgewater, Maryland. The firm provides due-diligence and business development services across the life sciences sector. They advise business development offices on product licensing and acquisition strategies and they support early-stage entrepreneurs with disruptive ideas and technologies. LifeTech also assists international financing agencies to facilitate the granting and lending of capital to improve economic welfare and societal health. LifeTech's research methods include (1) benchmarking (2) historic trend and meta-analysis (3) bias assessment and adjustment (4) decision analysis and Monte Carlo simulation (5) scenario analysis, back-testing and other statistical validation (6) advanced regression modeling and (7) risk and time-adjusted present value modeling. | Fondateur | 01/01/2003 |
Rare-X
 Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Directeur/Membre du Conseil | - |
| miCure Therapeutics Ltd | Directeur Général | 01/04/2022 |
Anciens postes connus de Ilana Fogelman
| Sociétés | Poste | Fin |
|---|---|---|
LifeTech Development Partners LP
 LifeTech Development Partners LP Investment ManagersFinance LifeTech Development Partners LP (LifeTech Development) is a venture capital subsidiary of LifeTech Research, Inc. founded in 2008 by Joel Braunstein. The firm is headquartered in Baltimore, Maryland. | Private Equity Investor | 01/01/2015 |
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/
 Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/ Investment Banks/BrokersFinance Merrill Lynch, Pierce, Fenner & Smith, Inc. (MLPFS) is the SEC-registered broker/dealer subsidiary of Merrill Lynch & Co., Inc., ultimately held by Charlotte-based Bank of America Corp. (NYSE: BAC). The firm was founded in 1958 and is headquartered in New York City. In 2010, Banc of America Securities LLC merged with MLPFS and the firm uses the trade name Bank of America Merrill Lynch. MLPFS's global strategy and economics team serves institutional and individual investors using a wide range of macroeconomic disciplines. Their analysis of global issues provides clients with investment ideas, market forecasts, macro overviews and specific sector recommendations across asset classes, regions and disciplines. Their equity research team conducts fundamental analysis on companies globally and provides institutional and retail clients with industry-specific and in-depth research and analysis on numerous industries. The firm's global fixed-income and equity-linked research focuses on fixed-income and equity derivatives, fixed-income strategy, convertibles, commodities, high-yield, mortgages, municipals and global foreign exchange. | Analyst-Equity | 10/06/2002 |
C2N Diagnostics LLC
 C2N Diagnostics LLC BiotechnologyHealth Technology C2N Diagnostics LLC is a private company that focuses on mechanism-based approaches to prevent or stop the progression of human neurological disorders. The company is based in St. Louis, MO. The company's lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including a?42, a?40, and apolipoprotein e isoforms. This test predicts brain amyloid plaques as determined by PET scan results and received a breakthrough device designation from the Food and Drug Administration in early 2019. C2N Diagnostics aims to bring accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring in the field of neurodegeneration and Alzheimer's disease. The company was founded by Ravi Kiron, Joel Bennett Braunstein, Ilana Fogelman. Joel Bennett Braunstein has been the CEO since incorporation. | Fondateur | - |
| Salomon Smith Barney | Corporate Officer/Principal | - |
Formation de Ilana Fogelman
| Harvard University | Graduate Degree |
| University of Sao Paulo | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/ Investment Banks/BrokersFinance Merrill Lynch, Pierce, Fenner & Smith, Inc. (MLPFS) is the SEC-registered broker/dealer subsidiary of Merrill Lynch & Co., Inc., ultimately held by Charlotte-based Bank of America Corp. (NYSE: BAC). The firm was founded in 1958 and is headquartered in New York City. In 2010, Banc of America Securities LLC merged with MLPFS and the firm uses the trade name Bank of America Merrill Lynch. MLPFS's global strategy and economics team serves institutional and individual investors using a wide range of macroeconomic disciplines. Their analysis of global issues provides clients with investment ideas, market forecasts, macro overviews and specific sector recommendations across asset classes, regions and disciplines. Their equity research team conducts fundamental analysis on companies globally and provides institutional and retail clients with industry-specific and in-depth research and analysis on numerous industries. The firm's global fixed-income and equity-linked research focuses on fixed-income and equity derivatives, fixed-income strategy, convertibles, commodities, high-yield, mortgages, municipals and global foreign exchange. | Finance |
LifeTech Research, Inc.
LifeTech Research, Inc. Investment Banks/BrokersFinance Founded in 2003, LifeTech Research, Inc. is an investment research, technology development and due diligence firm located in Edgewater, Maryland. The firm provides due-diligence and business development services across the life sciences sector. They advise business development offices on product licensing and acquisition strategies and they support early-stage entrepreneurs with disruptive ideas and technologies. LifeTech also assists international financing agencies to facilitate the granting and lending of capital to improve economic welfare and societal health. LifeTech's research methods include (1) benchmarking (2) historic trend and meta-analysis (3) bias assessment and adjustment (4) decision analysis and Monte Carlo simulation (5) scenario analysis, back-testing and other statistical validation (6) advanced regression modeling and (7) risk and time-adjusted present value modeling. | Finance |
LifeTech Development Partners LP
LifeTech Development Partners LP Investment ManagersFinance LifeTech Development Partners LP (LifeTech Development) is a venture capital subsidiary of LifeTech Research, Inc. founded in 2008 by Joel Braunstein. The firm is headquartered in Baltimore, Maryland. | Finance |
| Salomon Smith Barney | Finance |
C2N Diagnostics LLC
C2N Diagnostics LLC BiotechnologyHealth Technology C2N Diagnostics LLC is a private company that focuses on mechanism-based approaches to prevent or stop the progression of human neurological disorders. The company is based in St. Louis, MO. The company's lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including a?42, a?40, and apolipoprotein e isoforms. This test predicts brain amyloid plaques as determined by PET scan results and received a breakthrough device designation from the Food and Drug Administration in early 2019. C2N Diagnostics aims to bring accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring in the field of neurodegeneration and Alzheimer's disease. The company was founded by Ravi Kiron, Joel Bennett Braunstein, Ilana Fogelman. Joel Bennett Braunstein has been the CEO since incorporation. | Health Technology |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Technology Services |
| miCure Therapeutics Ltd |
